Lantheus touts ASCO GU talks with PSMA agent

AuntMinnie.com staff writers
Feb 4, 2021
2019 04 17 20 48 2514 Prostate 3 D 400

Lantheus Holdings, parent company of Lantheus Medical Imaging, along with its subsidiary Progenics Pharmaceuticals, announced their prostate-specific membrane antigen (PSMA) product candidates will be featured in three presentations at the upcoming 2021 American Society for Clinical Oncology Genitourinary (ASCO GU) virtual meeting.

Two abstracts cover the firm's PET/CT imaging agent for prostate cancer, PyL, and the third abstract relates to Lantheus' radiopharmaceutical therapeutic for metastatic castration-resistant prostate cancer, 1095.

Latest in Molecular Imaging
Scientific illustration showing chemical formulas, molecular structures, and atomic models on purple gradient background
Eckert & Ziegler gets GMP manufacturing authorization for Ac-225
October 28, 2026
Explore Innovations at EANM 2026
Sponsored
Explore Innovations at EANM 2026
October 1, 2026
Medical illustration of prostate gland surrounded by red cancer cells on blue background
AdvanCell reports data on Pb-212 PSMA therapy
October 26, 2026
Research presentation on nuclear medicine fragmentation showing 25 studies with PET imaging criteria analysis and expert interview
EANM: Is ‘research fragmentation’ holding back nuclear medicine?
October 21, 2026
Related Stories
2021 05 27 15 28 4419 2021 05 27 Pylarify Image Aunt Minnie pptx 400
Molecular Imaging
Lantheus gets FDA nod for Pylarify PET agent for prostate cancer
2021 01 16 00 14 5464 Prostate Cancer 400
Molecular Imaging
Lantheus subsidiary Exini secures CE Mark for PET/CT prostate software
2020 06 10 18 15 5134 Hands Shaking V4 400
Nuclear Medicine
Lantheus announces new R&D hires
Explore Innovations at EANM 2026
Sponsor Content
Explore Innovations at EANM 2026
More in Molecular Imaging
Eckert & Ziegler gets GMP manufacturing authorization for Ac-225
By AuntMinnieEurope.com staff writers
The firm is also planning Ac-225 production at its joint venture facility in China and further expansion in the U.S. and Germany.
October 28, 2026
Scientific illustration showing chemical formulas, molecular structures, and atomic models on purple gradient background
SIIM-CAIMI: 20% of advanced imaging prior auth denials get overturned
By Amerigo Allegretto
Advanced imaging prior authorization denials are overturned at a rate of five times that of all Medicare Advantage services.
October 27, 2026
PET/CT scan showing axial, sagittal, and coronal views with metabolic activity visualization in yellow and orange
AdvanCell reports data on Pb-212 PSMA therapy
By AuntMinnie.com staff writers
Eighty percent of patients had a prostate-specific antigen (PSA) decline of at least 50%, according to the company.
October 26, 2026
Medical illustration of prostate gland surrounded by red cancer cells on blue background
EANM: Is ‘research fragmentation’ holding back nuclear medicine?
By Will Morton
Well-designed studies require collaboration among nuclear medicine, medical oncology, urology, radiation oncology, and clinical trial support.
October 21, 2026
Research presentation on nuclear medicine fragmentation showing 25 studies with PET imaging criteria analysis and expert interview
Telix posts revenue growth in Q3
By AuntMinnie.com staff writers
For the period (end-September 30), Telix had group revenues of $245 million, up from $206 million in the same period last year.
October 21, 2026
Business analyst examining financial data charts and percentages through magnifying glass on laptop screen
GEHC begins global clinical evaluation of StarGuide GX SPECT/CT
By AuntMinnie.com staff writers
Participating sites include health centers in the U.S., Europe, and Asia.
October 20, 2026
GE HealthCare CT scanner with gray housing, purple accent ring, and sliding patient table
FAPI-PET detects more HCC lesions than FDG-PET
By Will Morton
Relative to F-18 FDG, F-18 FAPI-PET/CT produced staging changes in 19 of 32 patients undergoing initial staging, including six true upstagings.
October 20, 2026
Comparative PET/CT scan images showing [18F]FAPI and [18F]FDG imaging with MIP projections, fusion views, and CT cross-sections for medical diagnosis
EANM: Thomas Hope on what’s next in FAP-targeted theranostics
By Will Morton
The innovations and work being done to optimize FAP agents will likely "spill over" to other targets.
October 19, 2026
Clinical research presentation slide showing FAP RLT experience data table with patient outcomes across multiple institutions and speaker photo
Nuclidium, NorthStar sign Cu-67 supply and manufacturing deal
By AuntMinnie.com staff writers
Cu-67 is the therapeutic half of Nuclidium’s theranostic platform, which pairs it with copper-61 (Cu-61) for diagnostic imaging.
October 19, 2026
Hand holding glowing atom symbol with blue and gold light effects against blurred tech background
EANM: Next-generation PET scanner cuts imaging time to one minute
By Will Morton
The scanner's fastest images were rated more highly on average than those from a standard PET/CT scanner.
October 18, 2026
PET scan comparison showing SAFOV baseline and 1-minute and 5-minute time-point imaging with tracer uptake patterns
Capitol Imaging Services acquires Impression Imaging
By AuntMinnie.com staff writers
CIS said the deal is part of its expansion into molecular imaging and theranostics.
October 16, 2026
Two businessmen in suits shaking hands during a professional meeting
IBA gets order for 12 cyclotrons for U.S. PET tracer network
By AuntMinnie.com staff writers
A KIUBE 300 system typically costs between €2.5 million and €5 million.
October 16, 2026
IBA brand logo with white stylized text and circular symbol on green gradient background signage
Page 1 of 637
Next Page